filed in 2026 covering its full product portfolio. The combined patent portfolio spans 64 or more claims across a total addressable market of approximately 146.5 billion dollars globally.

Plopii Pouches are nootropic oral pouches delivering paraxanthine, Alpha-GPC, citicoline, L-theanine, Panax ginseng, and B vitamins via a proprietary isotonic buccal delivery system. The formulation is built on the Tripartite Cholinergic Enhancement architecture, engaging three mechanistically distinct and non-redundant cholinergic vectors simultaneously, a combination not covered by any prior patent or commercial product.

Plopii Migraine Relief is a patented OTC analgesic composition combining paraxanthine as a universal adjuvant analgesic enhancer with acetaminophen, aspirin, ibuprofen, or naproxen sodium. Paraxanthine replaces caffeine as the xanthine adjuvant with up to 3.5 times higher adenosine receptor potency and significantly reduced jitteriness, anxiety, and insomnia. Four formulation embodiments target the entire 30 billion dollar OTC headache market. Near-term commercialization is via patent licensing to established pharmaceutical companies. The company plans to develop the headache pill through Phase 3 Clinical Trials.

Plopii Energy is a 12 fl oz zero-sugar, zero-caffeine carbonated energy drink delivering 300 mg paraxanthine alongside a fully disclosed 2,842 mg active nootropic stack including taurine, L-tyrosine, Alpha-GPC, citicoline, L-theanine, Panax ginseng, and GanedenBC30 probiotic. It is the only energy drink using paraxanthine as its primary stimulant at the GRAS ceiling dose, with a dual cholinergic stack and a carbonation-stable probiotic.

All three product lines use paraxanthine as the core active compound, enabling shared supplier relationships, shared safety data, and a unified brand position. Plopii Pouches and Plopii Energy are classified as dietary supplements under DSHEA and require no FDA pre-market approval. The e-commerce platform at plopii.com is live.